Evaluating immunogenicity for PEGylated therapeutics requires specialized analytical approaches.

Pre-existing anti-PEG antibodies can complicate immunogenicity assessments and influence clinical interpretation. This poster examines assay strategies for detecting anti-PEG antibodies using surface plasmon resonance (SPR) and electrochemiluminescence (ECL), highlighting approaches for evaluating assay performance and addressing the unique challenges associated with PEGylated biopharmaceuticals.

Key highlights include:

• Comparison of SPR and ECL platforms for anti-PEG antibody detection
• Strategies for evaluating assay performance and analytical reliability
• Considerations for interpreting immunogenicity responses in PEGylated therapeutics
• Approaches for addressing the impact of pre-existing anti-PEG antibodies
• Practical insights for supporting immunogenicity assessments during clinical development

As PEGylated biopharmaceuticals continue to play an important role in therapeutic development, robust immunogenicity testing is essential for generating meaningful clinical data. See how complementary analytical technologies can support reliable anti-PEG antibody detection and improve immunogenicity assessments.